Mortality among papillary thyroid cancer patients by detection route: a hospital-based retrospective cohort study.

IF 3.5 2区 医学 Q2 ENDOCRINOLOGY & METABOLISM European Thyroid Journal Pub Date : 2023-11-06 Print Date: 2023-12-01 DOI:10.1530/ETJ-23-0127
Lan Wu, Salvatore Vaccarella, Chen-Yang Feng, Luigino Dal Maso, Yu Chen, Wei-Wei Liu, Miao-Bian Liang, Zike Zhang, Jun Yang, Su-Mei Cao, Mengmeng Li
{"title":"Mortality among papillary thyroid cancer patients by detection route: a hospital-based retrospective cohort study.","authors":"Lan Wu, Salvatore Vaccarella, Chen-Yang Feng, Luigino Dal Maso, Yu Chen, Wei-Wei Liu, Miao-Bian Liang, Zike Zhang, Jun Yang, Su-Mei Cao, Mengmeng Li","doi":"10.1530/ETJ-23-0127","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Incidence rates of papillary thyroid cancer (PTC) have increased rapidly, with incidentally detected cancers contributing a large proportion. We aimed to explore the impact of incidental detection on thyroid cancer-specific and competing mortality among PTC patients.</p><p><strong>Methods: </strong>We conducted a retrospective cohort study of PTC patients at a cancer center in Guangzhou. Baseline information on detection route and other covariates were collected between 2010 and 2018, and death outcome was followed up for each patient. Cumulative incidence functions were used to estimate the mortality risk of thyroid cancer and competing risk. Cause-specific hazard models were then utilized to explore the association between detection routes and PTC-specific and competing mortality.</p><p><strong>Results: </strong>Of the 2874 patients included, 2011 (70.0%) were detected incidentally, and the proportion increased from 36.9% in 2011 to 82.3% in 2018. During a median follow-up of 5.6 years, 42 deaths occurred, with 60% of them due to competing causes. The probability of competing mortality at 5 years in the non-incidental group and incidental group was 1.4% and 0.4%, respectively, and PTC-specific mortality in the non-incidental group and incidental group was 1.0% and 0.1%, respectively. After adjusting for covariates, the HRs of incidental detection were 0.13 (95% CI: 0.04-0.46; P = 0.01) and 0.47 (95% CI: 0.20-1.10; P = 0.10) on PTC-specific mortality and competing mortality, respectively.</p><p><strong>Conclusions: </strong>Incidental detection is associated with a lower risk of PTC-specific and competing mortality. Under the context of increasing magnitude of overdiagnosis, incorporation of detection route in clinical decision-making might be helpful to identify patients who might benefit from more extensive or conservative therapeutic strategies.</p>","PeriodicalId":12159,"journal":{"name":"European Thyroid Journal","volume":" ","pages":""},"PeriodicalIF":3.5000,"publicationDate":"2023-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10692677/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Thyroid Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1530/ETJ-23-0127","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/12/1 0:00:00","PubModel":"Print","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Incidence rates of papillary thyroid cancer (PTC) have increased rapidly, with incidentally detected cancers contributing a large proportion. We aimed to explore the impact of incidental detection on thyroid cancer-specific and competing mortality among PTC patients.

Methods: We conducted a retrospective cohort study of PTC patients at a cancer center in Guangzhou. Baseline information on detection route and other covariates were collected between 2010 and 2018, and death outcome was followed up for each patient. Cumulative incidence functions were used to estimate the mortality risk of thyroid cancer and competing risk. Cause-specific hazard models were then utilized to explore the association between detection routes and PTC-specific and competing mortality.

Results: Of the 2874 patients included, 2011 (70.0%) were detected incidentally, and the proportion increased from 36.9% in 2011 to 82.3% in 2018. During a median follow-up of 5.6 years, 42 deaths occurred, with 60% of them due to competing causes. The probability of competing mortality at 5 years in the non-incidental group and incidental group was 1.4% and 0.4%, respectively, and PTC-specific mortality in the non-incidental group and incidental group was 1.0% and 0.1%, respectively. After adjusting for covariates, the HRs of incidental detection were 0.13 (95% CI: 0.04-0.46; P = 0.01) and 0.47 (95% CI: 0.20-1.10; P = 0.10) on PTC-specific mortality and competing mortality, respectively.

Conclusions: Incidental detection is associated with a lower risk of PTC-specific and competing mortality. Under the context of increasing magnitude of overdiagnosis, incorporation of detection route in clinical decision-making might be helpful to identify patients who might benefit from more extensive or conservative therapeutic strategies.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
癌症甲状腺乳头状癌患者检测途径的死亡率:一项基于医院的回顾性队列研究。
背景:癌症(PTC)的发病率迅速上升,其中偶然发现的癌症占很大比例。我们旨在探讨偶然检测对PTC患者甲状腺癌特异性和竞争性死亡率的影响。方法:我们在广州癌症中心对PTC患者进行了回顾性队列研究。2010-2018年间收集了检测途径和其他协变量的基线信息,并对每位患者的死亡结果进行了随访。累计发病率函数用于估计甲状腺癌症的死亡率风险和竞争风险。然后利用病因特异性危险模型来探索检测途径与PTC特异性和竞争性死亡率之间的关系。结果:在纳入的2874名患者中,2011名(70.0%)是偶然发现的,这一比例从2011年的36.9%上升到2018年的82.3%。在5.6年的中位随访中,发生了42例死亡,其中60%是由于相互竞争的原因。非偶然组和偶然组在5年时竞争性死亡率的概率分别为1.4%和0.4%,非偶然组的PTC特异性死亡率为1.0%和0.1%。校正协变量后,PTC特异性和竞争性死亡率中偶然检测的HR分别为0.13(95%CI:0.04-0.46;P=0.01)和0.47(95%CI:0.20-1.10;P=0.010)。结论:偶然检测与PTC特异性和竞争性死亡率的风险较低有关。在过度诊断日益严重的背景下,将检测途径纳入临床决策可能有助于确定哪些患者可能受益于更广泛或更保守的治疗策略。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
European Thyroid Journal
European Thyroid Journal Medicine-Endocrinology, Diabetes and Metabolism
CiteScore
6.70
自引率
2.10%
发文量
156
期刊介绍: The ''European Thyroid Journal'' publishes papers reporting original research in basic, translational and clinical thyroidology. Original contributions cover all aspects of the field, from molecular and cellular biology to immunology and biochemistry, from physiology to pathology, and from pediatric to adult thyroid diseases with a special focus on thyroid cancer. Readers also benefit from reviews by noted experts, which highlight especially active areas of current research. The journal will further publish formal guidelines in the field, produced and endorsed by the European Thyroid Association.
期刊最新文献
Development of an enzyme-linked immunosorbent assay for newborns dried blood spot thyroglobulin. Real word outcomes of cabozantinib therapy in poorly differentiated thyroid carcinoma. Toward a treatment for thyroid hormone transporter MCT8 deficiency - achievements and challenges. Effects of iodine contrast media on thyroid function - a prospective study. Thyrotoxic periodic paralysis - a retrospective study from Southern India.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1